Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × tomivosertib × Breast × Clear all
NCT03318562 2019-07-18

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Effector Therapeutics

Phase 2 Terminated
3 enrolled
BreastGastrointestinal

Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡